Compare ELMD & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELMD | IFRX |
|---|---|---|
| Founded | 1992 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.1M | 225.5M |
| IPO Year | 2010 | 2017 |
| Metric | ELMD | IFRX |
|---|---|---|
| Price | $23.00 | $1.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $48.50 | $8.29 |
| AVG Volume (30 Days) | 38.8K | ★ 1.1M |
| Earning Date | 11-10-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.94 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $54,716,000.00 | N/A |
| Revenue This Year | $11.55 | N/A |
| Revenue Next Year | $10.94 | N/A |
| P/E Ratio | $72.69 | ★ N/A |
| Revenue Growth | ★ 13.83 | N/A |
| 52 Week Low | $22.67 | $0.80 |
| 52 Week High | $47.40 | $2.95 |
| Indicator | ELMD | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 27.51 | 27.04 |
| Support Level | $23.03 | $0.81 |
| Resistance Level | $24.99 | $1.07 |
| Average True Range (ATR) | 1.24 | 0.15 |
| MACD | -0.29 | -0.02 |
| Stochastic Oscillator | 8.17 | 0.00 |
Electromed Inc is a United States-based company that develops, manufactures and markets airway clearance products that apply High Frequency Chest Wall Oscillation (HFCWO) therapy in pulmonary care for patients of all ages. The company markets its products in the U.S. to the homecare and hospital markets. Its product includes the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The company operates in a single segment: developing, manufacturing, and marketing medical equipment. The company generates revenue from Homecare, Hospital, Homecare Distributor, and Other.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.